Susan Dent
0000-0002-9183-9340
Duke Cancer Institute
13 papers found
Refreshing results…
Cardiovascular Diseases Increase Cancer Mortality in Adults: NHANES‐Continuous Study
Allostatic Load/Chronic Stress and Cardiovascular Outcomes in Patients Diagnosed With Breast, Lung, or Colorectal Cancer
Breast cancer risk reduction: Beyond pharmacologic intervention
Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer
Moving Beyond Cardiotoxicity Detection to Prevention: A Pharmacologic Review
Circulating Cardiovascular Biomarkers in Cancer Therapeutics‐Related Cardiotoxicity: Review of Critical Challenges, Solutions, and Future Directions
Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer
The underutilization of preventive cardiovascular measures in patients with cancer: an analysis of the Behavioural Risk Factor Surveillance System, 2011–22
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis
Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experience
Missing publications? Search for publications with a matching author name.